Greater Noida
Uttar Pradesh has taken a significant step towards becoming a global hub for advanced medical technology with the Yamuna Expressway Industrial Development Authority allocating 10 acres of land to Shukra Pharmaceuticals Limited under the Medical Devices Park initiative. The Letter of Intent was issued under the Invest UP framework, marking one of the most ambitious healthcare manufacturing projects in the region.
The project aims to establish a state-of-the-art medical technology manufacturing facility that will focus on life-saving and next-generation healthcare solutions. The initiative is aligned with the state’s broader vision of strengthening indigenous manufacturing, reducing import dependence, and positioning India as a global leader in medical technology innovation.
The Letter of Intent was handed over in the presence of YEIDA Chief Executive Officer Rakesh Kumar Singh and ACEO Shailendra Bhatia. Representatives from Shukra Pharmaceuticals Limited present at the event included Dr Minakshi Late, Group Chief Executive Officer and Global Head, Gaurav Shokeen, Chief Operating Officer, Anil Kumar Verma, Vice President, and Kamini Bharti, Business Unit Head.
The proposed facility at the Medical Devices Park will focus on the manufacturing of some of the world’s most advanced and critical medical technologies. A key highlight of the project is the production of Boron Neutron Capture Therapy (BNCT), regarded as one of the most advanced treatment modalities for complex and difficult-to-treat cancer cases. BNCT is globally recognised for its precision-based approach and its potential to significantly improve outcomes for cancer patients.
In addition to oncology-focused innovations, the facility will manufacture a comprehensive range of radiology and imaging equipment. These include CT scanners, MRI machines, PET scanners, X-ray systems and ultrasonography machines. The project will also cover the production of anaesthesia systems along with respiratory care solutions essential for intensive care units and operation theatres, strengthening critical care infrastructure within the country.
A major component of the manufacturing portfolio will be cardiovascular implants designed to address serious heart conditions. These include heart valves, stents and Left Ventricular Assist Devices (LVADs), which are vital for patients suffering from advanced cardiac disorders. Alongside this, special emphasis will be placed on respiratory support products such as ventilators and oxygen concentrators, which have become indispensable in modern healthcare delivery.
The project is also set to make a strong entry into the rapidly evolving field of medical robotics. The facility will develop advanced robotic systems for healthcare applications, including soft tissue surgical robots, orthopaedic robotic systems with implants, dental robotic systems with implants, and neuro-spine robotic systems. These technologies are expected to enhance surgical precision, reduce recovery times and improve overall patient safety while bringing cutting-edge surgical solutions closer to Indian hospitals.
Beyond manufacturing, the Medical Devices Park facility will also focus on diagnostics and medical education. In-vitro diagnostic solutions such as point-of-care testing devices and advanced analysers will be produced to enable faster and more accurate diagnosis. To strengthen clinical training and minimise patient risk, the project includes the establishment of medical simulators for doctors, nurses and paramedical professionals. These simulators will use advanced simulation technologies to enhance skills and improve preparedness across healthcare disciplines.
The project represents a significant economic and employment opportunity for the region. With a capital expenditure investment of Rs 587 crore, the facility is expected to generate over 900 direct jobs and nearly 2,000 indirect employment opportunities. Employment will span multiple domains including manufacturing, research and development, quality assurance, regulatory affairs, sales, marketing and allied services.
A strong focus will be placed on local hiring and skill development, ensuring that youth from Uttar Pradesh gain access to high-value employment and specialised training. By localising advanced medical technologies, Shukra Pharmaceuticals aims to reduce reliance on imports while ensuring the availability of world-class medical devices at affordable costs within India.
The initiative reflects a collaborative approach between the government and industry to build a future where advanced medical technology is not treated as a luxury, but as a fundamental right that is accessible, affordable and impactful. Officials believe the project will play a pivotal role in strengthening India’s healthcare ecosystem, boosting innovation, and reinforcing the country’s position as a self-reliant global leader in medical technology.
—
